Menu

The Roots of Schizophrenia

Researchers link disease-associated mutations to excitatory and inhibitory signaling in the brain.

Jun 4, 2015
Jef Akst

FLICKR, ALLAN AJIFOThe genetic causes of schizophrenia, a psychiatric disorder that affects around 1 percent of the population, are complex, to say the least. But new research has begun to produce clues pointing to the disruption of the brain’s chemical balance as the root cause of the disorder. Most recently, scientists found that genetic mutations previously linked to schizophrenia play a role in neuronal excitatory and inhibitory signaling. They published their results yesterday (June 3) in Neuron.

“We’re finally starting to understand what goes wrong in schizophrenia,” lead author Andrew Pocklington from Cardiff University’s Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics said in a press release. “We now have what we hope is a pretty sizeable piece of the jigsaw puzzle that will help us develop a coherent model of the disease, while helping us to rule out some of the alternatives.”

The same team of researchers first linked schizophrenia mutations to excitatory signaling back in 2011. The new work, which compared genetic data from 11,355 schizophrenia patients and 16,416 healthy controls, confirms these previous findings and adds inhibitory signaling to the list of functions that may be disrupted by disease-associated mutations, suggesting that it is the imbalance between the two that may be at the heart of the disorder.

“This work builds on our understanding of the genetic causes of schizophrenia, unravelling how a combination of genetic faults can disrupt the chemical balance of the brain,” Hugh Perry, chair of the MRC Neuroscience and Mental Health Board, said in the press release. “In the future, this work could lead to new ways of predicting an individual’s risk of developing schizophrenia and form the basis of new targeted treatments that are based on an individual’s genetic makeup.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.